NCT03947320Unknown3 期
A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Paediatric Patients With Severe Haemophilia A.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 70
- 主要终点
- Annualized Bleeding Rate
研究概览
简要总结
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from Visit 1 and prophylaxis with SCT800 shall continue for 24 consecutive weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- — 至 12 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Aged <12 years ;
- •Male severe (central laboratory tested FVIII:C <1%) hemophilia A patients;
- •Previously received FVIII treatment (prophylactic or bleeding treatment), have the relevant records and are verified to have accumulated EDs ≥150 days（6≤age<12years old）and EDs >50 days（age <6 years old）;
- •The bleeding treatment records of at least 3 months before screening can be obtained;
- •Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result <0.6 BU/mL);
- •HIV negative; if HIV positive, the viral load <200 particles/uL or <400,000 copies/mL, and HIV patients must satisfy CD4+ count >200/μL;
- •The patient or his guardian voluntarily signed the Informed Consent Form.
排除标准
- •Known allergy to any coagulation factor VIII or any excipient; known allergy to bovine, rodent or hamster bovine;
- •Has a history or family history of blood coagulation factor VIII inhibitor;
- •Platelet count <100 × 109/L;
- •Clinical liver function test ((glutamic-pyruvic transaminase, glutamic-pyruvic transaminase) ≥ five times the upper limit of normal (ULN) or clinical kidney function test （creatinine) ≥ two times the ULN;
- •International normalized ratio (INR) >1.5;
- •Patients with other coagulation dysfunction diseases in addition to hemophilia A;
- •Patients who used any anticoagulant or anti-platelet treatment (including non-steroidal anti-inflammatory drugs [NSAIDs]) within 1 weeks before the first drug administration or who regularly (e.g., daily, every other day) use anticoagulant or anti-platelet treatment within the clinical trial period;
- •Patients who used immunomodulator(e.g., immunoglobulin, corticosteroids,alpha-interferon, prednisone [>10 mg/day and >7 days], or comparable drugs, other than anti-retroviral chemotherapy) within two weeks before the first administration of the study drug or during the clinical trial period;
- •Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of study drug.
- •Patients with other clinically significant diseases, alcoholism, drug abuse, mental disorders or intellectual disabilities;
- •Patients with other severe or clinical significant diseases verified by the investigator to be unable to benefit from the clinical study;
- •Patients who participated in other clinical studies within one month before the first drug administration (except FVIII trials) and patients who participated in other FVIII clinical trials after signing the Informed Consent Form;
研究组 & 干预措施
Recombinant Human Coagulation FVIII
Experimental
Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
干预措施: Recombinant Human Coagulation FVIII (Drug)
结局指标
主要结局
Annualized Bleeding Rate
时间窗: up to 24 weeks
Annualized Bleeding Rate（ABR） can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)
次要结局
- Clearance(Predose within 30 min，15 min±2 min、1 hour±5 min，10 hours±30 min，24 hours±1hours and 48 hours±2 hours post-dose)
- Annualized joint bleeding rate(up to 24 weeks)
- FVIII incremental in-vivo recovery(Predose within 30 min，15 min±2 min)
- Elimination Half Life(Predose within 30 min，15 min±2 min、1 hour±5 min，10 hours±30 min，24 hours±1hours and 48 hours±2 hours post-dose)
- Bleeding event treatment efficacy(up to 24 weeks)
研究者
相似试验
已完成
3 期
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Squamous Non-Small Cell LungNCT02367781Hoffmann-La Roche723
Unknown
3 期
A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and FeverNeutropenia and FeverNCT05108545CSPC ZhongQi Pharmaceutical Technology Co., Ltd.93
进行中（未招募）
3 期
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Non Small Cell Lung Carcinoma NSCLCNCT03003962AstraZeneca669
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490
进行中（未招募）
3 期
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic LeukemiaNCT04075292AstraZeneca155